- Home
- FUBO vs OCS Comparison
FUBO vs OCS Comparison
Compare FUBO & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FUBO
- OCS
- Stock Information
- Founded
- FUBO 2009
- OCS 2003
- Country
- FUBO United States
- OCS Switzerland
- Employees
- FUBO N/A
- OCS N/A
- Industry
- FUBO Broadcasting
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- FUBO Industrials
- OCS Health Care
- Exchange
- FUBO Nasdaq
- OCS Nasdaq
- Market Cap
- FUBO 1.1B
- OCS 1.0B
- IPO Year
- FUBO 2020
- OCS N/A
- Fundamental
- Price
- FUBO $3.12
- OCS $19.28
- Analyst Decision
- FUBO Buy
- OCS Strong Buy
- Analyst Count
- FUBO 5
- OCS 3
- Target Price
- FUBO $4.79
- OCS $35.33
- AVG Volume (30 Days)
- FUBO 12.3M
- OCS 30.1K
- Earning Date
- FUBO 08-05-2025
- OCS 05-08-2025
- Dividend Yield
- FUBO N/A
- OCS N/A
- EPS Growth
- FUBO N/A
- OCS N/A
- EPS
- FUBO 0.22
- OCS N/A
- Revenue
- FUBO $1,636,735,000.00
- OCS $847,333.00
- Revenue This Year
- FUBO N/A
- OCS $18.70
- Revenue Next Year
- FUBO $9.48
- OCS $1,059.78
- P/E Ratio
- FUBO $14.23
- OCS N/A
- Revenue Growth
- FUBO 13.18
- OCS N/A
- 52 Week Low
- FUBO $1.10
- OCS $10.79
- 52 Week High
- FUBO $6.45
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- FUBO 48.24
- OCS 51.81
- Support Level
- FUBO $3.12
- OCS $18.64
- Resistance Level
- FUBO $3.38
- OCS $19.73
- Average True Range (ATR)
- FUBO 0.16
- OCS 0.58
- MACD
- FUBO -0.05
- OCS -0.07
- Stochastic Oscillator
- FUBO 16.38
- OCS 36.57
About FUBO fuboTV Inc.
FuboTV Inc is a sports-first, live TV streaming company offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, FuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. It offers subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality suited to their preferences. The company has one operating segment, the streaming business. Geographically, the company generates a majority of its revenue from the United States and also has a presence in other markets.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.